Ellen Duong et al. demonstrated that, in contrast to DC1s which rely on cross-presentation, ISG+ DCs activate anti-tumor CD8+ T cell responses by acquiring and presenting intact tumor-derived peptide-MHC I complexes through MHC-I dressing, which is enhanced by type I interferon [42]. The gene discussed is CD8A; the disease is neoplasm.